IQVIA (IQV) Scheduled to Post Earnings on Wednesday

IQVIA (NYSE:IQVGet Free Report) will be releasing its earnings data before the market opens on Wednesday, February 14th. Analysts expect IQVIA to post earnings of $2.57 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

IQVIA Stock Performance

NYSE:IQV opened at $217.88 on Tuesday. The business has a 50 day moving average of $219.72 and a 200 day moving average of $211.12. The company has a market capitalization of $39.76 billion, a price-to-earnings ratio of 36.62, a PEG ratio of 2.49 and a beta of 1.48. IQVIA has a 1-year low of $167.42 and a 1-year high of $234.92. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.79 and a quick ratio of 0.79.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IQV. Citigroup boosted their target price on IQVIA from $190.00 to $225.00 and gave the stock a “neutral” rating in a research report on Monday, December 11th. Guggenheim decreased their price target on IQVIA from $253.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Truist Financial lifted their price target on IQVIA from $240.00 to $286.00 and gave the stock a “buy” rating in a research note on Thursday, January 4th. Barclays lifted their price target on IQVIA from $215.00 to $260.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Finally, JPMorgan Chase & Co. decreased their price target on IQVIA from $262.00 to $239.00 and set an “overweight” rating on the stock in a research note on Monday, November 13th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $244.31.

View Our Latest Research Report on IQVIA

Insider Buying and Selling

In related news, insider Kevin C. Knightly sold 13,117 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $214.03, for a total value of $2,807,431.51. Following the sale, the insider now directly owns 7,347 shares of the company’s stock, valued at $1,572,478.41. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On IQVIA

Several hedge funds have recently added to or reduced their stakes in IQV. HighTower Advisors LLC boosted its holdings in IQVIA by 2.4% in the first quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock worth $1,168,000 after acquiring an additional 118 shares in the last quarter. Prudential PLC bought a new stake in IQVIA in the first quarter worth $741,000. Baird Financial Group Inc. boosted its holdings in IQVIA by 2.3% in the first quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock worth $23,021,000 after acquiring an additional 2,201 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in IQVIA by 59.0% in the first quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock worth $90,000 after acquiring an additional 144 shares in the last quarter. Finally, Covestor Ltd lifted its holdings in shares of IQVIA by 82.2% during the first quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 250 shares in the last quarter. 86.82% of the stock is owned by institutional investors.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also

Earnings History for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.